Hyaluronan synthesis is required for IL-2-mediated T cell proliferation

被引:39
作者
Mahaffey, Christie L. [1 ]
Mummert, Mark E. [1 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Dermatol, Dallas, TX 75390 USA
关键词
D O I
10.4049/jimmunol.179.12.8191
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hyaluronan (HA) is a glycosaminoglycan composed of N-acetylglucosamine and glucuronic acid subunits. Previous studies have suggested that CD44 expressed by T cells bind exogenous HA for their proliferation. However, HA endogenously synthesized by T cells may participate in their autocrine proliferation. In this study, we examined the role of endogenous HA in T cell proliferation using the highly specific HA synthase inhibitor, 4-methylumbelliferone (4-MU). We found that 4-MU inhibited the mitogen-induced synthesis of HA by T cells. Moreover, 4-MU inhibited T cell proliferation in a dose-dependent manner when cells were cultured with different stimuli, including Con A, PMA/ionomycin, and allogeneic spleen cells. Furthermore, 4-MU inhibited mitogen-stimulated IL-2 secretion, suggesting that HA may play a role in the production of this cytokine. Addition of IL-2 to T cells treated with 4-MU and Con A reversed the block in cell proliferation, showing that impaired IL-2 production is a likely mechanism for the inhibited division of T cells. Surprisingly, an anti-CD44 Ab antagonistic for HA binding did not reduce IL-2 secretion or T cell proliferation. Importantly, 4-MU did not alter the surface expression of CD44 or the ability of CD44 to bind to HA. Thus, HA-mediated IL-2 production and T cell proliferation are CD44 independent. Our results strongly suggest that HA synthesized by T cells themselves is critical for their IL-2-mediated proliferation and have revealed a previously unrecognized role for endogenous HA in T cell biology.
引用
收藏
页码:8191 / 8199
页数:9
相关论文
共 48 条
  • [1] Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme
    Camenisch, TD
    Spicer, AP
    Brehm-Gibson, T
    Biesterfeldt, J
    Augustine, ML
    Calabro, A
    Kubalak, S
    Klewer, SE
    McDonald, JA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (03) : 349 - 360
  • [2] Carter LL, 2002, EUR J IMMUNOL, V32, P634, DOI 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO
  • [3] 2-9
  • [4] Chakrabarti R, 2000, J CELL BIOCHEM, V76, P37, DOI 10.1002/(SICI)1097-4644(20000101)76:1<37::AID-JCB5>3.0.CO
  • [5] 2-6
  • [6] Deed R, 1997, INT J CANCER, V71, P251, DOI 10.1002/(SICI)1097-0215(19970410)71:2<251::AID-IJC21>3.0.CO
  • [7] 2-J
  • [8] Requirement for CD44 in activated T cell extravasation into an inflammatory site
    DeGrendele, HC
    Estess, P
    Siegelman, MH
    [J]. SCIENCE, 1997, 278 (5338) : 672 - 675
  • [9] CD44 and its ligand hyaluronate mediate rolling under physiologic flow: A novel lymphocyte-endothelial cell primary adhesion pathway
    DeGrendele, HC
    Estess, P
    Picker, LJ
    Siegelman, MH
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) : 1119 - 1130
  • [10] GALANDRINI R, 1994, J IMMUNOL, V153, P21